AMGN241018C305000
- 19.92
- +2.07+11.60%
Amgen Newsroom
Amgen Analyst Ratings
Truist Financial Downgrades Amgen(AMGN.US) to Hold Rating, Announces Target Price $333
Morgan Stanley Adjusts Price Target on Amgen to $319 From $316
Morgan Stanley Keeps Their Hold Rating on Amgen (AMGN)
Amgen Analyst Ratings
Barclays Keeps Their Hold Rating on Amgen (AMGN)
Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating
DBS Maintains Amgen(AMGN.US) With Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen Analyst Ratings
Cantor Fitzgerald Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $405
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
RBC Capital Sticks to Its Buy Rating for Amgen (AMGN)
Amgen Analyst Ratings
Baird Reiterates Underperform on Amgen, Maintains $215 Price Target
Baird Maintains Amgen(AMGN.US) With Sell Rating, Maintains Target Price $215
Leerink Partners Maintains Amgen(AMGN.US) With Hold Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $344 to $381
TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)